People

Joshua D Lee
Joshua D. Lee, MD, MSc
NYU Langone Health - Associate Professor, Department of Population Health, Division of General Medicine and Clinical Innovation
Education
MD, University of Tennessee College of Medicine
MSc, Weill Cornell Graduate School of Medical Sciences
AB, Art and Archeology, Princeton University
Research Interests
Addiction pharmacotherapies, Primary care, Criminal justice
BIO
Joshua D. Lee is an Associate Professor of Population Health and Medicine/General Internal Medicine and Clinical Innovation at NYU Langone Health. He is a clinician researcher focused on addiction pharmacotherapies, and is Director of the NYU ABAM Fellowship in Addiction Medicine. His research models the use of addiction pharmacotherapies in primary care and criminal justice populations. He has conducted multiple NIH and other clinical trials examining the use of extended-release naltrexone and buprenorphine opioid treatments in outpatient criminal justice involved-adults, in soon-to-be released jail inmates, and in community detox settings. Research on extended-release naltrexone for alcohol treatment has focused on primary care medical management. Dr. Lee graduated Princeton University (AB), the University of Tennessee School of Medicine (MD), and Weill Cornell Graduate School of Medical Sciences (MSc). He completed a residency and chief residency in Primary Care Internal Medicine at NYU/Bellevue Hospital Center and is certified in Addiction Medicine. He is currently an attending physician at Bellevue Hospital and in the New York City jails.
Projects
Principal Investigator, Impact of Jail-Based Methadone on Overdose, Recidivism, HIV and Health Outcomes, and Costs in New York City, 2011-2017. Active
Principal Investigator, Long-Acting Buprenorphine vs. Naltrexone Opioid Treatments in CJS-Involved Adults. Active
Principal Investigator, Extended-Release Naltrexone Opioid Treatment at Jail-to-Community Re-Entry. Completed
Principal Investigator, Extended-Release vs. Oral Naltrexone Alcohol Treatment in Primary Care. Completed
Publications

Recent

Greiner MG, Shulman M, Choo TH, Scodes J, Pavlicova M, Campbell ANC, Novo P, Fishman M, Lee JD, Rotrosen J, Nunes EV (2021).
Naturalistic follow-up after a trial of medications for opioid use disorder: Medication status, opioid use, and relapse
Journal of Substance Abuse Treatment, 131, 108447. doi: 10.1016/j.jsat.2021.108447.

Waddell EN, Springer SA, Marsch LA, Farabee D, Schwartz RP, Nyaku A, Reeves R, Goldfeld K, McDonald RD, Malone M, Cheng A, Saunders EC, Monico L, Gryczynski J, Bell K, Harding K, Violette S, Groblewski T, Martin W, Talon K, Beckwith N, Suchocki A, Torralva R, Wisdom JP, Lee JD (2020).
Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults (EXIT-CJS)
Journal of Substance Abuse Treatment, 128, 108389. doi: 10.1016/j.jsat.2021.108389. PMCID: PMC8384640.

Lee JD, Malone M, McDonald R, Cheng A, Vasudevan K, Tofighi B, Garment A, Porter B, Goldfeld KS, Matteo M, Mangat J, Katyal M, Giftos J, MacDonald R (2021).
Comparison of treatment retention of adults with opioid addiction managed with extended-release buprenorphine vs daily sublingual buprenorphine-naloxone at time of release from jail
JAMA Network Open, 4 (9), e2123032. doi: 10.1001/jamanetworkopen.2021.23032. PMCID: PMC8427378.

Nunes EV, Scodes JM, Pavlicova M, Lee JD, Novo P, Campbell ANC, Rotrosen J (2021).
Sublingual buprenorphine-naloxone compared with injection naltrexone for opioid use disorder: Potential utility of patient characteristics in guiding choice of treatment
American Journal of Psychiatry, 178 (7), 660-671. doi: 10.1176/appi.ajp.2020.20060816.

Gryczynski J, Lee JD, Dusek K, McDonald R, Sharma A, Malone M, Monico LB, Cheng A, DeVeaugh-Geiss A, Chilcoat HD (2021).
Use of non–prescribed buprenorphine in the criminal justice system: Perspectives of individuals recently released from incarceration
Journal of Substance Abuse Treatment, 127, 108349. doi: 10.1016/j.jsat.2021.108349.


Notable

Lee JD, Friedmann PD, Kinlock TW, Nunes EV, Boney TY, Hoskinson RA, Wilson D, McDonald R, Rotrosen J, Gourevitch MN, Gordon M, Fishman M, Chen DT, Bonnie RJ, Cornish JW, Murphy SM, O'Brien CP (2016).
Extended-release naltrexone to prevent opioid relapse in criminal justice offenders
New England Journal of Medicine, 374 (13), 1232-1242. doi: 10.1056/NEJMoa1505409. PMCID: PMC5454800.

Lee JD, McDonald R, Grossman E, McNeely J, Laska E, Rotrosen J, Gourevitch MN (2015).
Opioid treatment at release from jail using extended-release naltrexone: A pilot proof-of-concept randomized effectiveness trial
Addiction, 110 (6), 1008-1014. doi: 10.1111/add.12894.

Lee JD, Grossman E, Truncali A, Rotrosen J, Rosenblum A, Magura S, Gourevitch M (2012).
Buprenorphine-naloxone maintenance following release from jail
Substance Abuse, 33 (1), 40-47. doi: 10.1080/08897077.2011.620475. PMCID: PMC3310898.

Dr. Lee's MyBibliography Profile
Selected Press